Western Slope Laboratory

CLIA Laboratory Citation Details

2
Total Citations
12
Total Deficiencyies
6
Unique D-Tags
CMS Certification Number 23D1047507
Address 1197 Rochester Road Suite K, Troy, MI, 48083
City Troy
State MI
Zip Code48083
Phone(248) 307-1168

Citation History (2 surveys)

Survey - January 13, 2025

Survey Type: Standard

Survey Event ID: S58811

Deficiency Tags: D5217 D5217

Summary:

Summary Statement of Deficiencies D5217 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(c)(1) At least twice annually, the laboratory must verify the accuracy of any test or procedure it performs that is not included in subpart I of this part. This STANDARD is not met as evidenced by: . Based on record review and interview with the Quality Director, the laboratory failed to verify the accuracy of its quantitative oral fluid toxicology testing for 70 of 95 analytes listed on the laboratory's test menu. Findings include: 1. A review of the laboratory's test menu revealed the laboratory performs quantitative oral fluid toxicology testing for 95 total analytes. 2. A review of the laboratory's proficiency testing records between January 2023 and January 2025 revealed a lack of twice annual verification of accuracy for the following oral fluid analytes in 2023 and 2024: a. 2-Hydroxyethlyflurazepam b. 4-Methylethcathinone c. 7-Aminoclonazepam d. 7- Aminoflunitrazepam e. 7-Hydroxymitragynine f. Alpha Hydroxyalprazolam g. Alpha Hydroxymidazolam h. Alpha Hydroxytriazolam i. Alpha PVP j. Acetaminophen k. Amitriptyline l. Carisoprodol m. Chloridiazepoxide n. Citalopram o. Clomipramine p. Cyclobenzaprine q. Desalkylflurazepam r. Despiramine s. Desmethoxyyangonin t. Desmethyldoxepin u. Dextromethorphan v. Dextrorphan w. Dihydrocodeine x. Dihydrokavain y. Doxepin z. EDDP aa. Ethylone bb. Fluoxetine cc. Gabapentin dd. Hydromorphone ee. Imipramine ff. Kavain gg. Ketamine hh. Lorazepam ii. maprotiline jj. MDEA kk. Meperidine ll. Meprobamate mm. Methylhexanamine nn. Methylone oo. Methylphenidate pp. Mitragynine qq. N-Desmethlytapentadol rr. Naloxone ss. Naltrexone tt. Naproxen uu. Norhydrocodone vv. Norketamine ww. Normeperidine xx. Noroxycodone yy. Nortriptyline zz. o-Desmethyl-cis-tramadol aaa. o-Desmethylvenlafaxine bbb. Paroxetine ccc. Pentazocine ddd. Pentadrone eee. Phentermine fff. Pregabalin ggg. Propoxyphene hhh. Ritalinic Acid iii. Setraline jjj. STS135 kkk. Tapentadol lll. Tramadol mmm. Trimipramine nnn. UR144 ooo. Venlafaxine ppp. XLR11 qqq. Zolpidem 3. An interview on 1/13/25 with the Quality Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- Director at 12:45 pm revealed the laboratory had been using a combination of urine and oral fluid testing events to verify the accuracy of its oral fluid testing analytes and confirmed the analytes listed above were not verified with oral fluid testing. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - April 22, 2019

Survey Type: Standard

Survey Event ID: 3DP111

Deficiency Tags: D5407 D5433 D5439 D6018 D6019 D5407 D5433 D5439 D6018 D6019

Summary:

Summary Statement of Deficiencies D5407 PROCEDURE MANUAL CFR(s): 493.1251(d) Procedures and changes in procedures must be approved, signed, and dated by the current laboratory director before use. This STANDARD is not met as evidenced by: . Based on procedure manual review and interview with the Quality Assurance Supervisor (QAS), the laboratory director failed to approve, sign, and date each procedure biennially for 2 of 2 years. Findings include: 1. A review of "Laboratory SOPs and Guidelines" and the"Quality Systems Management" procedure revealed the laboratory director failed to approve, sign, and date procedures biennially for 2017 and 2018. Procedures include: a. Instrument Cleaning #27, last approved March 2015. b. Laboratory Receiving #31, last approved June 2015. c. Calibrating Centrifuges #41, no approval dates between July 2013 and October 2018. d. Glassware Cleaning #50, last approved November 2015. e. Creating a Validation Plan #1020, last approved August 2016. 2. An interview on 4/22/19 at 10:35 am with the QAS confirmed the procedures listed above were not approved, signed or dated biennially according to the laboratory's "Quality Systems Management" procedure. D5433 MAINTENANCE AND FUNCTION CHECKS CFR(s): 493.1254(b)(1) For equipment, instruments, or test systems developed in-house, commercially available and modified by the laboratory, or maintenance and function check protocols are not provided by the manufacturer, the laboratory must establish a maintenance protocol that ensures equipment, instrument, and test system performance that is necessary for accurate and reliable test results and test result reporting. The laboratory must perform and document the maintenance activities specified in paragraph (b)(1)(i) of this section. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 4 -- This STANDARD is not met as evidenced by: . Based on record review and interview with the Quality Assurance Supervisor (QAS), the laboratory failed to perform and document weekly and monthly maintenance for 3 of 5 Ab Sciex Qtrap 5500 instruments according to the manufacturer. Findings include: 1. Review of the weekly, monthly, and quarterly maintenance logs revealed a lack of documentation and performance of the following Ab Sciex Qtrap 5500 instruments in 2017 and 2018: a. Ab Sciex Qtrap 5500 (MSG) 1. Weekly maintenance was not performed as follows: a. 1 of 4 weeks in October, November, and December of 2017. b. 1 of 4 weeks in January and February of 2018. c. 3 of 4 weeks in June 2018. 2. Monthly maintenance was not performed during the following months: a. November 2017. b. January, June, July, August, September, October, November, and December of 2018. b. Ab Sciex Qtrap 5500 (MSB) 1. Weekly maintenance was not performed as follows: a. 1 of 4 weeks in August, October, November, and December of 2017. b. 2 of 4 weeks in September 2017. c. 2 of 4 weeks in May and September of 2018. d. 3 of 4 weeks in June and August of 2018. e. 4 of 4 weeks in July, October, November, and December of 2018. 2. Monthly maintenance was not performed during the following months: a. September and October 2017. b. July, August, October, November, and December 2018. c. Ab Sciex Qtrap 5500 (MSF) 1. Weekly maintenance was not performed as follows: a. 1 of 4 weeks in October and December of 2017. b. 2 of 4 weeks in May and June of 2018. c. 3 of 4 weeks in September 2018. d. 4 of 4 weeks in July, August, October, November, and December of 2018. 2. Monthly maintenance was not performed for the following months: a. November 2017. b. May, June, July, August, September, October, November, and December of 2018. 2. Interview on 4/22/19 at 2:25 pm with the QAS confirmed the lack of documentation and performance of weekly and monthly maintenance for 3 of 5 Ab Sciex Qtrap 5500 analyzers. D5439 CALIBRATION AND CALIBRATION VERIFICATION CFR(s): 493.1255(b) Unless otherwise specified in this subpart, for each applicable test system the laboratory must do the following: Perform and document calibration verification procedure - (b)(1) Following the manufacturer's calibration verification instructions; (b)(2) Using the criteria verified or established by the laboratory under 493.1253(b)(3) -- (b)(2)(i) Including the number, type, and concentration of the materials, as well as acceptable limits for calibration verification; and (b)(2)(ii) Including at least a minimal (or zero) value, a mid-point value, and a maximum value near the upper limit of the range to verify the laboratory's reportable range of test results for the test system; and (b)(3) At least once every 6 months and whenever any of the following occur: (b)(3)(i) A complete change of reagents for a procedure is introduced, unless the laboratory can demonstrate that changing reagent lot numbers does not affect the range used to report patient test results, and control values are not adversely affected by reagent lot number changes. (b)(3)(ii) There is major preventive maintenance or replacement of critical parts that may influence test performance. (b)(3)(iii) Control materials reflect an unusual trend or shift, or are outside of the laboratory's acceptable limits, and other means of assessing and correcting unacceptable control values fail to identify and correct the problem. (b)(3)(iv) The laboratory's established schedule for verifying the reportable range for patient test results requires more frequent calibration verification. -- 2 of 4 -- This STANDARD is not met as evidenced by: . Based on record review and interview with the Quality Assurance Supervisor (QAS), the laboratory failed to perform chemistry calibration verification (linearity) at least once every 6 months as required for 4 (1 event in 2017, 2 events in 2018, and 1 event in 2019) out of 5 events required. Findings include: 1. A record review revealed a lack of documentation showing linearity was not completed at least every 6 months for the Carolina Liquid Chemistries CLC 6410 analyzer since it was installed 2/28/17. One event in 2017, two events in 2018, and one event in 2019 of linearity testing were not completed for the following tests: a. Specific Gravity b. Oxidants c. pH d. Urine Creatinine 2. An interview with the QAS on 4/22/19 at 1:18 pm confirmed linearity for the tests listed above was not completed at least every 6 months in 2017, 2018, and 2019. D6018 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(iii) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(iii) Ensure that all proficiency testing reports received are reviewed by the appropriate staff to evaluate the laboratory's performance and to identify any problems that require

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access